| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| b' \\xc5\\x9eeng\\xc3\\xbcl Kocamer \\xc5\\x9eahin, Bahadir Demir, Abdurrahman Altinda\\xc4\\x9. Remission of treatment-resistant obsessive-compulsive disorder with 600 milligrams of fluvoxamine daily: a case report. International clinical psychopharmacology. 2023-02-08. PMID:36752695.' |
first-line drugs for obsessive-compulsive disorder (ocd) pharmacotherapy are selective serotonin reuptake inhibitors (ssri). |
2023-02-08 |
2023-08-14 |
Not clear |
| Naoki Amada, Tsuyoshi Hirose, Mikio Suzuki, Yusuke Kakumoto, Takashi Futamura, Kenji Maeda, Tetsuro Kikuch. Synergistic anti-depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice. Neuropsychopharmacology reports. 2023-01-17. PMID:36649966. |
selective serotonin reuptake inhibitors (ssris) are used to treat major depressive disorder (mdd) and other psychiatric disorders (e.g., obsessive compulsive disorder, social anxiety disorder, and panic disorder). |
2023-01-17 |
2023-08-14 |
mouse |
| Peter J van Roessel, Giacomo Grassi, Elias N Aboujaoude, José M Menchón, Michael Van Ameringen, Carolyn I Rodrígue. Treatment-resistant OCD: Pharmacotherapies in adults. Comprehensive psychiatry. vol 120. 2022-11-11. PMID:36368186. |
serotonin reuptake inhibitor (sri) medications are well established as first-line pharmacotherapeutic treatment for obsessive-compulsive disorder (ocd). |
2022-11-11 |
2023-08-14 |
Not clear |
| Jéssica Fernandes da Silva, Leticia Mitsuko Taguchi, Erinete da Silva Leite, Amanda Ribeiro de Oliveir. mCPP-induced behavioral changes in OCD research: a systematic review of rodent studies. Neuroscience. 2022-11-04. PMID:36332691. |
meta-chlorophenylpiperazine (mcpp) was one of the first compounds used in clinical and preclinical studies that demonstrated the role of serotonin in obsessive-compulsive disorder (ocd). |
2022-11-04 |
2023-08-14 |
rat |
| Xiao-Lin Li, Shan-Qing Huang, Tao Xiao, Xi-Pei Wang, Wan Kong, Shu-Jing Liu, Zi Zhang, Ye Yang, Shan-Shan Huang, Xiao-Jia Ni, Hao-Yang Lu, Ming Zhang, Yu-Guan Wen, De-Wei Shan. Pharmacokinetics of immediate and sustained-release formulations of paroxetine: Population pharmacokinetic approach to guide paroxetine personalized therapy in chinese psychotic patients. Frontiers in pharmacology. vol 13. 2022-09-29. PMID:36172189. |
paroxetine is one of the most potent selective serotonin reuptake inhibitors (ssris) approved for treating depression, panic disorder, and obsessive-compulsive disorder. |
2022-09-29 |
2023-08-14 |
Not clear |
| John Lz Nyirenda, Mario Sofroniou, Ingrid Toews, Agata Mikolajewska, Cornelius Lehane, Ina Monsef, Aesha Abu-Taha, Andy Maun, Miriam Stegemann, Christine Schmucke. Fluvoxamine for the treatment of COVID-19. The Cochrane database of systematic reviews. vol 9. 2022-09-14. PMID:36103313. |
fluvoxamine is a selective serotonin reuptake inhibitor (ssri) that has been approved for the treatment of depression, obsessive-compulsive disorder, and a variety of anxiety disorders; it is available as an oral preparation. |
2022-09-14 |
2023-08-14 |
Not clear |
| Luca Pellegrini, Kabir Garg, Arun Enara, David Shimon Gottlieb, David Wellsted, Umberto Albert, Keith R Laws, Naomi A Fineber. Repetitive transcranial magnetic stimulation (r-TMS) and selective serotonin reuptake inhibitor-resistance in obsessive-compulsive disorder: A meta-analysis and clinical implications. Comprehensive psychiatry. vol 118. 2022-08-02. PMID:35917621. |
repetitive transcranial magnetic stimulation (r-tms) and selective serotonin reuptake inhibitor-resistance in obsessive-compulsive disorder: a meta-analysis and clinical implications. |
2022-08-02 |
2023-08-14 |
Not clear |
| Ahmed Naguy, Anubhuti Singh, Fajer Q M AlDarweesh, Bibi Alamir. Possible Toxic Serotonin Syndrome in an Adolescent With Obsessive-Compulsive Disorder Precipitated by Esomeprazole. The primary care companion for CNS disorders. vol 24. issue 4. 2022-07-25. PMID:35878563. |
possible toxic serotonin syndrome in an adolescent with obsessive-compulsive disorder precipitated by esomeprazole. |
2022-07-25 |
2023-08-14 |
Not clear |
| Christiana Bratiotis, Jordana Muroff, Nancy X Y Li. Hoarding Disorder: Development in Conceptualization, Intervention, and Evaluation. Focus (American Psychiatric Publishing). vol 19. issue 4. 2022-06-24. PMID:35747296. |
cognitive-behavioral therapy (cbt) with exposure and response prevention and selective serotonin reuptake inhibitor medications traditionally used to treat obsessive-compulsive disorder are generally not efficacious for people with hoarding problems. |
2022-06-24 |
2023-08-14 |
Not clear |
| Pei Wang, Wenjie Gu, Jian Gao, Changhong Wang, Jianqun Fang, Maorong Hu, Hui Xiang, Bin Li, Na Liu, Wenxin Tang, Xijin Wang, Yanbin Jia, Yi Li, Yuqi Cheng, Zhen Tang, Helen Blair Simpson, Dan J Stein, Zhen Wan. Protocol for a Pragmatic Trial of Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD (PROCEED). Frontiers in psychiatry. vol 13. 2022-06-02. PMID:35651818. |
selective serotonin reuptake inhibitors (ssris) are the first-line pharmacotherapy for obsessive-compulsive disorder (ocd), but a large proportion of patients do not achieve remission after an adequate ssri trial. |
2022-06-02 |
2023-08-13 |
human |
| Miaohan Deng, Yuan Wang, Shunying Yu, Qing Fan, Jianyin Qiu, Zhen Wang, Zeping Xia. Exploring Association Between Serotonin and Neurogenesis Related Genes in Obsessive-Compulsive Disorder in Chinese Han People: Promising Association Between DMRT2, miR-30a-5p, and Early-Onset Patients. Frontiers in psychiatry. vol 13. 2022-05-31. PMID:35633798. |
exploring association between serotonin and neurogenesis related genes in obsessive-compulsive disorder in chinese han people: promising association between dmrt2, mir-30a-5p, and early-onset patients. |
2022-05-31 |
2023-08-13 |
Not clear |
| Satish Suhas, Palash Kumar Malo, Vijay Kumar, Thomas Gregor Issac, Nellai K Chithra, Binukumar Bhaskarapillai, Y C Janardhan Reddy, Naren P Ra. Treatment strategies for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A network meta-analysis of randomized controlled trials. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2022-05-26. PMID:35615998. |
treatment strategies for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a network meta-analysis of randomized controlled trials. |
2022-05-26 |
2023-08-13 |
Not clear |
| Jasmine Brar, Ajeet Sidana, Nidhi Chauhan, Manoj Kumar Baja. A randomized, open-label pilot trial of selective serotonin reuptake inhibitors on neuropsychological functions in patients with obsessive compulsive disorder. Journal of psychiatric research. vol 151. 2022-05-22. PMID:35598501. |
a randomized, open-label pilot trial of selective serotonin reuptake inhibitors on neuropsychological functions in patients with obsessive compulsive disorder. |
2022-05-22 |
2023-08-13 |
Not clear |
| Che Yu Kuo, Kao Chin Chen, I Hui Lee, Huai-Hsuan Tseng, Nan Tsing Chiu, Po See Chen, Yen Kuang Yang, Wei Hung Chan. Serotonin Modulates the Correlations between Obsessive-compulsive Trait and Heart Rate Variability in Normal Healthy Subjects: A SPECT Study with [ Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 20. issue 2. 2022-04-25. PMID:35466098. |
serotonin modulates the correlations between obsessive-compulsive trait and heart rate variability in normal healthy subjects: a spect study with [ the impact of serotonergic system on obsessive-compulsive disorder (ocd) is well studied. |
2022-04-25 |
2023-08-13 |
human |
| Antonio Tundo, Loretta Salvati, Luca Cieri, Viviana Balestrini, Daniela Di Spigno, Floriana Orazi, Marica Iommi, Roberta Necc. Serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. A prospective observational study. International journal of psychiatry in clinical practice. 2022-03-24. PMID:35323098. |
serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. |
2022-03-24 |
2023-08-13 |
Not clear |
| Antonio Tundo, Loretta Salvati, Luca Cieri, Viviana Balestrini, Daniela Di Spigno, Floriana Orazi, Marica Iommi, Roberta Necc. Serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. A prospective observational study. International journal of psychiatry in clinical practice. 2022-03-24. PMID:35323098. |
six in ten patients with obsessive-compulsive disorder (ocd) do not respond to the first-line treatments with serotonin reuptake inhibitor (sri) or cognitive behavioural therapy including exposure and response prevention (cbt/erp), and several do not respond to second-line treatments, i.e., sri-second generation antipsychotic (sga) or sri-cbt/erp augmentation. |
2022-03-24 |
2023-08-13 |
Not clear |
| Igor D Bandeira, Daniel H Lins-Silva, Vitor Breseghello Cavenaghi, Ingrid Dorea-Bandeira, Daniela Faria-Guimarães, Judah L Barouh, Ana Paula Jesus-Nunes, Graziele Beanes, Lucca S Souza, Gustavo C Leal, Gerard Sanacora, Euripedes C Miguel, Aline S Sampaio, Lucas C Quarantin. Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. Harvard review of psychiatry. vol 30. issue 2. 2022-03-10. PMID:35267254. |
first-line treatment for obsessive-compulsive disorder (ocd) includes exposure and response prevention behavioral therapy and serotonin reuptake inhibitors, particularly in combination. |
2022-03-10 |
2023-08-13 |
Not clear |
| Najmeh Shahini, Ali Talaei, Mohammadreza Shalbafan, Farhad Faridhosseini, Maliheh Ziae. Effects of Celecoxib Adjunct to Selective Serotonin Reuptake Inhibitors on Obsessive-Compulsive Disorder. Basic and clinical neuroscience. vol 12. issue 4. 2022-02-14. PMID:35154589. |
effects of celecoxib adjunct to selective serotonin reuptake inhibitors on obsessive-compulsive disorder. |
2022-02-14 |
2023-08-13 |
Not clear |
| Faezeh Nikzad, Seyed Alireza Sadjadi, Amir Hooshang Mohammadpour, Maliheh Ziaee, Fatemeh Behdani, Seyedeh Maryam Naghibi, Seyedeh Narges Nejatifard, Mahdieh Ghanbari, Ali Akhondpour Mantegh. Adjunct Triptorelin in the Treatment of Obsessive-Compulsive Disorder in Clients Receiving Selective Serotonin Reuptake Inhibitors (SSRIs). Iranian journal of psychiatry. vol 16. issue 4. 2022-01-27. PMID:35082857. |
adjunct triptorelin in the treatment of obsessive-compulsive disorder in clients receiving selective serotonin reuptake inhibitors (ssris). |
2022-01-27 |
2023-08-13 |
Not clear |
| Edna B Foa, Helen Blair Simpson, Thea Gallagher, Michael G Wheaton, Marina Gershkovich, Andrew B Schmidt, Jonathan D Huppert, Patricia Imms, Raphael B Campeas, Shawn Cahill, Christina DiChiara, Steven D Tsao, Anthony Puliafico, Daniel Chazin, Anu Asnaani, Kelly Moore, Jeremy Tyler, Shari A Steinman, Arturo Sanches-LaCay, Sandy Capaldi, Ívar Snorrason, Elizabeth Turk-Karan, Donna Vermes, Eyal Kalanthroff, Anthony Pinto, Gabriella E Hamlett, Rachel Middleton, Chang-Gyu Hahn, Bin Xu, Page E Van Meter, Martha Katechis, David Rosenfiel. Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial. JAMA psychiatry. 2022-01-26. PMID:35080598. |
serotonin reuptake inhibitors (sris) are the only medications approved for obsessive-compulsive disorder (ocd), yet most patients taking sris exhibit significant symptoms. |
2022-01-26 |
2023-08-13 |
Not clear |